NCT05056519View on ClinicalTrials.gov

The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

PHASE1UnknownINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

March 30, 2022

Conditions
Influenza Prevention
Interventions
BIOLOGICAL

Live Attenuated Influenza Vaccine

Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.

BIOLOGICAL

Live Attenuated Influenza Vaccine placebo

Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.

Trial Locations (1)

050021

RECRUITING

Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang

Sponsors
All Listed Sponsors
collaborator

He Bei province Center for Disease control and prevention

UNKNOWN

lead

Changchun BCHT Biotechnology Co.

INDUSTRY